Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-A51 in Advanced Liposarcoma and CIC-Rearranged Sarcoma
NCT06414434Phase 1Active, not recruiting
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BTX-A51 in Liposarcoma and CIC-rearranged sarcoma (2 arms). Primary endpoint: Adverse Events. Started Sep 2024; status: active, not recruiting.
02
Drugs
BTX-A51
03
Conditions
LiposarcomaCIC-rearranged sarcoma
Beyond the preview
Go deeper on NCT06414434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414434.